Introduction: WM is a rare subtype of lymphoma, identified by the presence of IgM paraprotein, infiltration of clonal, small lymphoplasmacytic B cells in the bone marrow, and the somatic mutation, MYD88 L265P, which is observed in over 90% of WM patients. We previously identified two rare variants at 6p25.3 (EXOC2) and 14q32.13 (TCL1) that were significantly associated with an increased risk of WM/LPL (PMID: 30305637). However, the genetic basis for WM/LPL predisposition remains largely unknown. We conducted the largest WM/LPL GWAS to discover further germline susceptibility loci for WM/LPL.
Methods: Our meta-analysis discovery set included 1,707 cases and 58,328 controls of European ancestry from the InterLymph Consortium, genotyped on a high-density SNP array and imputed to TOPMed, providing over 10 million common variants for association testing. Germline genetic loci with suggestive significance (P<5x10-6) were selected for replication in four independent sets (570 cases and 771,770 controls; UK Biobank, Copenhagen Hospital Biobank, FinnGen, Mayo Clinic), giving us a total of 2,277 WM/LPL cases and 831,098 controls. Conditional and sensitivity analyses were performed considering family history and sex. A transcriptome-wide association study (TWAS) was performed using FUSION with expression quantitative trait loci (eQTL) data from GTEx and Young Finns Study in whole blood, lymphocytes, and other tissues. Functional annotations were done using FUMA, F-MAGMA, FORGE, and OpenTarget. Colocalization was measured using CoLoC with whole blood gene expression data.
Results & Discussion: We identified 11 germline genetic loci associated with WM/LPL risk that replicated and reached genome-wide significance (P< 5x10-8), including the two known loci on 6p25.3 and 14q32.13 and nine novel loci in the following regions: 6p25.3 (n=2 independent loci), 2q37.1, 9p13.2, 6p21.32, 10q23.31, 16q21, 1p31.1, and 15q15.1. Four of the discovered variants showed strong associations with WM/LPL [odds ratios (ORs) >10]. Enrichment was observed for enhancer and promoter elements in B-cells (FDR q < 0.01), and gene-based and colocalization analyses identified several potential biological pathways. Colocalization analyses show the intronic PAX5 risk variant on 9p (OR=1.5, P= 2.3x10-25) associated with whole blood eQTL expression of PAX5, which plays an essential role in regulating lymphoid progenitors to the B-lymphocyte lineage, as well as RP11-297B17.3 (RNA gene, antisense to PAX5). In addition, GWAS have shown this variant is in linkage disequilibrium (LD) with GWAS loci for CD20 on IgD+ CD38- B cell that represents a specific immunophenotype that helps identify and characterize B cells involved with WM and other similar conditions. The 2q37.1 (SP140) locus (OR=1.6, P=1.2x10-33) contains variants linked to chronic lymphocytic leukemia (CLL) and autoimmune diseases, including multiple sclerosis and Crohn's disease. This locus is important in chromatin-mediated gene regulation, suggesting a significant role in the immune system. The specific variant influences exon-skipping and potentially protein expression, altering the gene's function. The variants on 10q23.31 in FAS (OR=1.3, P=4.4x10-13) and 15q15.1 (OR=1.2, P=8.5x10-11) in BCL2 modifying factor (BMF), are in strong LD with known CLL susceptibility variants. The 15q variant is also linked with multiple lymphoid leukemia GW significant SNPs. Sex-specific analyses identified one novel locus at 20q13.33 associated with the expression of ZGPAT and UCKL1 in males (OR=1.9, P=9.5x10-10). TWAS identified associations with CRHR1 and CDKN2A; overexpression of both are shown to be associated with an increased risk of WM/LPL. Expression of CDKN2A has been linked to childhood acute lymphoblastic leukemia, while CRHR1 has been associated with breast cancer risk.
Conclusions: Our study, the largest GWAS of WM to date, has identified 11 susceptibility loci, including two previously known and nine novel regions. The findings underscore the genetic complexity of WM, with the PAX5 and SP140 loci implicated in both chromatin-mediated gene regulation and immune system functions. These insights not only enhance our understanding of WM predisposition but also pave the way for future research focused on functional understanding of these loci, potentially leading to new therapeutic strategies.
Sucheston-Campbell:Roche: Current equity holder in publicly-traded company, Ended employment in the past 24 months. D'Sa:Sanius Health: Consultancy; BeiGene: Consultancy, Honoraria, Other: Travel, accommodations, expenses, Research Funding, Speakers Bureau; Cellectar: Honoraria. Cerhan:BMS: Research Funding; Protagonist Therapeutics: Other: SMC; GenMab: Research Funding; Genentech: Research Funding. Treon:AbbVie/Pharmacyclics: Honoraria, Research Funding; Eli Lilly: Research Funding; BeiGene, Inc.: Honoraria, Research Funding; Parexel: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal